TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18632181
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (as in arm B) plus capecitabine (625 mg/m² twice daily on days 5-18 q 4 weeks)
Study: 16907846
Drug: No antepartum
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antepartum treatment
Study: 14691614
Drug: Carbamazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (600 mg daily except 200 mg daily for the first 2 days)
Study: 11297908
Drug: Scopolamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine nasal spray (0.2%)
Study: 9550476
Drug: Iloprost (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (50 microg orally twice daily)
Study: 3076492
Drug: Dydrogesterone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (10 mg b.d.)
Study: 23497020
Drug: Fermented turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented turmeric powder (FTP) 3.0 g per day for 12 weeks
Study: 23497020
Drug: Placebo 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3.0 g per day for 12 weeks
Study: 17875549
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of omega-3-polyunsaturated fatty acids
Study: 9824785
Drug: K4MgCit2 (49
Approvals — FDA: no, EMA: no, PMDA: no
Description: K4MgCit2 (49 mEq K, 25 mEq Mg, and 74 mEq citrate/day)
Study: 9824785
Drug: K3MgHCit2 (49
Approvals — FDA: no, EMA: no, PMDA: no
Description: K3MgHCit2 (49 mEq K, 33 mEq Mg, and 98 mEq citrate/day)
Study: 9824785
Drug: K5MgCit2Cl (49
Approvals — FDA: no, EMA: no, PMDA: no
Description: K5MgCit2Cl (49 mEq K, 20 mEq Mg, 10 mEq Cl and 59 mEq citrate/day)
Study: 7661060
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (53% of patients treated with a thrombolytic agent in 1992)
Study: 7661060
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (no thrombolytic therapy in 1966 and 1981-1983)
Study: 6815
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of ipecac orally
Study: 6815
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg apomorphine subcutaneously
Study: 25632066
Drug: C‐GEMOX (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐GEMOX (500 mg/m² cetuximab plus GEMOX: 800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Study: 25632066
Drug: GEMOX (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX (800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Study: 21613792
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment without inhibitors of the renin-angiotensin-aldosterone system (n = 21)
Study: 16953530
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (morphine 5 mg at time zero and 5 mg at 20 minutes, ketorolac 15 mg at time zero and 15 mg at 20 minutes)
Study: 16953530
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (5 mg at time zero and 5 mg at 20 minutes)
Study: 16953530
Drug: Ketorolac alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac alone (15 mg at time zero and 15 mg at 20 minutes)
Study: 14764773
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate daily for 2 years
Study: 14764773
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol plus 1 mg norethisterone acetate daily for 2 years (HRT)
Study: 14764773
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alendronate and HRT for 2 years
Study: 11590393
Drug: Wheat ω-5
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat ω-5 gliadin IgE antibody testing
Study: 11590393
Drug: Oral wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral wheat challenge
Study: 3312625
Drug: 9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/kg methylprednisolone (steroid-treated)
Study: 31547713
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy in children
Study: 31547713
Drug: Cluster immunotherapy
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster immunotherapy in children
Study: 31547713
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy in adults
Study: 31547713
Drug: Cluster immunotherapy
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster immunotherapy in adults
Study: 27647770
Drug: Ormeloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ormeloxifene (60 mg twice per week)
Study: 27647770
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptive (ethinyl estradiol 30 μg with desogestrel 150 μg on days 1-21 for 6 months)
Study: 23059433
Drug: Active reflexology
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active reflexology treatment to areas of the feet corresponding to the heart
Study: 23059433
Drug: Control reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control reflexology treatment to other areas of the feet
Study: 11960019
Drug: Biological motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological motion stimulus based on a limited lifetime technique
Study: 12452304
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (group 1)
Study: 29040268
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (goal systolic pressure < 120 mm Hg)
Study: 23563218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (supportive therapy)
Study: 21440734
Drug: Low-dose rabbit
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rabbit antithymocyte globulin (LoD-rATG, 3-5 mg/kg)
Study: 21440734
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of rabbit antithymocyte globulin (7-10 mg/kg)
Study: 16909140
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus irinotecan (IG) - 300 mg m(‐2) on day 8, gemcitabine on days 1 and 8, repeated every 3 weeks.
Study: 16909140
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (G) - 900 mg m(‐2) on days 1, 8, and 15 every 4 weeks.
Study: 11426345
Drug: Polypharmacy cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy cream (testosterone 0.8%, isosorbide dinitrate 0.5%, co‐dergocrine mesylate 0.06%)
Study: 11426345
Drug: Testosterone cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream (0.8%)
Study: 10965083
Drug: Nitrolingual-Spray
Normalized name: nitroglycerin Mucosal Spray [Nitrolingual]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrolingual-Spray
Study: 10965083
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) tablets
Study: 8981709
Drug: Combined temporal
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined temporal corneal phacoemulsification and superior trabeculectomy with low-dose 5-FU
Study: 8981709
Drug: Trabeculectomy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy alone with low-dose 5-FU
Study: 1290475
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of oral enterically coated 4‐aminosalicylic acid
Study: 26531051
Drug: Topical natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical natamycin or voriconazole (corrected for treatment arm)
Study: 24523562
Drug: D1-like receptor
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-like receptor activation with l-DOPA (25 mg)
Study: 24523562
Drug: D1-like receptor
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-like receptor activation with l-DOPA (100 mg)
Study: 24523562
Drug: D1-like receptor
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-like receptor activation with l-DOPA (200 mg)
Study: 17438710
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy and radiotherapy
Study: 16239090
Drug: Extended-release clarithromycin
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release clarithromycin (CLA-ER) 1000 mg once a day for 5 days
Study: 16239090
Drug: Telithromycin (TELI)
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin (TELI) 800 mg once a day for 5 days
Study: 10223677
Drug: Indirect therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect therapy (group 2)
Study: 10223677
Drug: Direct with
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct with indirect therapy (group 3)
Study: 10223677
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group 1)
Study: 22366535
Drug: l‐dopa alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐dopa alone
Study: 22366535
Drug: STN‐DBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: STN‐DBS plus l‐dopa
Study: 22366535
Drug: Without STN‐DBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without STN‐DBS and without l‐dopa
Study: 22366535
Drug: Reflex blinking
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflex blinking (STN‐DBS and l‐dopa)
Study: 19022007
Drug: Prophylactic low-energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low-energy shock wave therapy (SWT) applied to the site of vein harvesting after wound closure (n = 50)
Study: 12185103
Drug: CPA‐5‐100 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA‐5‐100 (5 mg/day CPA + 100 mg/week TE)
Study: 12185103
Drug: CPA‐5‐200 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA‐5‐200 (5 mg/day CPA + 200 mg/week TE)
Study: 1992688
Drug: Iodide salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodide salt administered to group A (n = 17)
Study: 19321400
Drug: Bladder pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder pressure measurement (BP) using 50 mL of sterile saline instilled into the bladder, measured in the supine position.
Study: 17257473
Drug: Oxymorphone extended
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended release (5- to 10-mg increments every 12 h, every 3-7 days)
Study: 11599506
Drug: HMB in
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB in time release capsule (TRH)
Study: 8303754
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate at 0.6 mg/kg per day
Study: 8303754
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate at 2.0 mg/kg per day
Study: 8303754
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate at 6.0 mg/kg per day
Study: 8303754
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of Tirilazad
Study: 23652908
Drug: tretinoin plus
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tretinoin plus topical corticosteroids
Study: 23652908
Drug: vehicle plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle plus topical corticosteroid
Study: 21910803
Drug: Anti-TNF-α treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α treatment
Study: 16055455
Drug: Non-NSAID (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-NSAID (paracetamol and codeine)
Study: 12532174
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg s.c./24 h
Study: 7480564
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of RS 15385
Study: 7480564
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of RS 15385
Study: 2257249
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment for 1 year
Study: 2257249
Drug: Estro-progestative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estro-progestative treatment for 1 year
Study: 2257249
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens treatment for 6 months post-oophorectomy
Study: 24137971
Drug: Ascoril (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascoril (combined broncholytic and expectorant drug)
Study: 24137971
Drug: Ambroxol (mucolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (mucolytic agent)
Study: 20193328
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of pirarubicin (THP) at 1 hour before TUR-BT (30 mg/50 ml, 0.5 hours)
Study: 20193328
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of pirarubicin (THP) at 24 hours before TUR-BT (30 mg/50 ml, 0.5 hours)
Study: 17426207
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg) for 12 weeks
Study: 7911736
Drug: Cladribine 4
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine 4 mg/m2/day
Study: 7911736
Drug: Cladribine 6
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine 6 mg/m2/day
Study: 7911736
Drug: Cladribine 8
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine 8 mg/m2/day
Study: 28315160
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) at 2.0 g kg-1 of the diet for 4 weeks prior to MCLR injection
Study: 28315160
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) at 1.0 g kg-1 of the diet for 4 weeks prior to MCLR injection
Study: 28315160
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) at 0.5 g kg-1 of the diet for 4 weeks prior to MCLR injection
Study: 28315160
Drug: MCLR intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCLR intraperitoneal injection (150 μg kg-1 BW)
Study: 26289437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tastants (quinine, rebaudioside A, monosodium glutamate)
Study: 19690450
Drug: Bathing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bathing with clear water twice weekly (Group B)
Study: 19690450
Drug: Washing with
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washing with a washcloth moistened with clear water twice weekly (Group W)
Study: 11097666
Drug: Air group
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air group (2 mL of air)
Study: 11097666
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (2 mL of 0.9% saline)
Study: 9357887
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 0 ng/ml
Study: 9357887
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 25 ng/ml
Study: 9357887
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 50 ng/ml
Study: 9357887
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 100 ng/ml
Study: 9357887
Drug: Alfentanil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil administration
Study: 8211353
Drug: Aggressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive therapy for myocardial ischemia and infarction in elderly patients
Study: 28956535
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants with platelet rich fibrin (PRF)
Study: 28956535
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants without PRF (control)
Study: 28956535
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants with PRF
Study: 23116485
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg) with FF/VI (200/25 μg)
Study: 18847427
Drug: Low-dose corticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticoids
Study: 18847427
Drug: Anti-TNF-alpha agents
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-alpha agents
Study: 2968263
Drug: doxifluridine 4000
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: doxifluridine 4000 mg/m2
Study: 2968263
Drug: fluorouracil 450
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil 450 mg/m2 i.v.
Study: 28364493
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (N = 26)
Study: 28364493
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (N = 30)
Study: 26567275
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of treadmill and lower-limb resistance supervised exercise training (SET) for 12 weeks
Study: 25123230
Drug: internet-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based self-help problem solving treatment (PST) for affective symptoms
Study: 22365697
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular.
Study: 22365697
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular, based on bursal size.
Study: 19732200
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy (SC)
Study: 17101267
Drug: Expanding collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanding collagen tablets
Study: 17101267
Drug: Small sustained
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small sustained release hydrocolloid tablets
Study: 15010336
Drug: 6‐h continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐h continuous infusion of [1,2‐(13)C(2)]taurine (3.1 +/- 0.2 micromol x kg(‐1) x h(‐1))
Study: 15010336
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of [(13)C(2)]taurine (3.0 +/- 0.1 micromol/kg)
Study: 15010336
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tracer
Study: 9610692
Drug: 5-fluorouracil (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (370 mg/m2) plus folinic acid (200 mg/m2) administered daily for 5 days every 4 weeks for 6 cycles
Study: 7601177
Drug: Flurbiprofen LATTM
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen LATTM (40 mg) applied via a nonwoven polyester patch every 12 hours for 14 days
Study: 7601177
Drug: Placebo (patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (patch without active ingredient)
Study: 29401546
Drug: Levothyroxine and
Normalized name: Levothyroxine and liothyronine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine and iodide therapy
Study: 23795985
Drug: IV ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV ranibizumab (0.5 mg, 0.05 cc)
Study: 23795985
Drug: IV bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV bevacizumab (1.5 mg, 0.06 cc)
Study: 19752567
Drug: Intranasal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal lavage with hypertonic saline solution 3 times daily
Study: 19752567
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no local therapy)
Study: 12030615
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg dexamethasone
Study: 2142700
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg dexamethasone